BTC Digital Ltd. (METX)
NASDAQ (CM) NASDAQ (CM) Primary 
ME Therapeutics Announces That Its First Therapeutic mRNA Candidate Shows Encouraging Anti-Cancer Efficacy in Vivo
Vancouver, British Columbia--(Newsfile Corp. - January 14, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that its first therapeutic mRNA candidate from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics") has demonstrated encouraging anti-cancer activity in a mouse model of colorectal cancer. The Company is planning follow-up studies to confirm the anti-cancer effect as well as to further characterize the mechanism of action of the lead mRNA candidate.
ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce the start of efficacy testing of the first two mRNA formulations from its strategic collaboration with NanoVation Therapeutics Inc. ("NanoVation Therapeutics"). As previously disclosed, ME Therapeutics aims to enhance the precision and efficacy of myeloid cell-delivered mRNA therapeutics in vivo to develop potential new cancer therapies by leveraging the cutting-edge lipid nanoparticle (LNP) technologies of NanoVation Therapeutics.
